El interés en corto de Chemomab Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Chemomab Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Chemomab Therapeutics (NASDAQ:CMMB) Bolsa, Informe de interés en corto

Chemomab Therapeutics

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics Ltd

Macro Economic Events

News

Econ #s

Economics

USA Gasoline Inventories A Build Of 2.054M Barrels Vs A Draw Of 4.407M Barrels Prior

WIIM

QUBT

Quantum Computing shares are trading higher after the company announced it received a second order for its TFLN photonic chip foundry from the University of Texas.

USA EIA Weekly Distillates Stocks A Draw Of 0.114M Barrels Vs A Draw Of 1.394M Barrels Prior

Macro Notification

General

USA Crude Oil Inventories A Build Of 0.545M Barrels Vs  A Build Of 2.089M Barrels Prior

TransUnion's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRU#NYSE">TRU</a>) short percent of float has fallen 5.88% since its last report. The company recently reported that it has 4.35 million shares sold short, which is 2.24% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.47 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>TransUnion Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732116623_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for TransUnion has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing TransUnion's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, TransUnion's peer group average for short interest as a percentage of float is 2.95%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

(TRU) - Analyzing TransUnion's Short Interest

Kenvue's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) short percent of float has risen 23.31% since its last report. The company recently reported that it has 38.50 million shares sold short, which is 2.01% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.3 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Kenvue Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732116617_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Kenvue has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Kenvue's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Kenvue's peer group average for short interest as a percentage of float is 5.61%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

KVUE

How Is The Market Feeling About Kenvue?

Reinsurance Gr's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RGA#NYSE">RGA</a>) short percent of float has fallen 8.06% since its last report. The company recently reported that it has 288 thousand shares sold short, which is 0.57% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Reinsurance Gr Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732116612_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Reinsurance Gr has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Reinsurance Gr's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Reinsurance Gr's peer group average for short interest as a percentage of float is 1.66%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Reinsurance Gr's Recent Short Interest

TD Cowen analyst Thomas Boyes maintains PureCycle Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCT#NASDAQ">PCT</a>) with a Buy and raises the price target from $10 to $15.

Price Target

Analyst Ratings

TD Cowen Maintains Buy on PureCycle Technologies, Raises Price Target to $15

DRMA

Dermata Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS results.

U.S. stocks were lower, with the Nasdaq Composite falling more than 200 points on Wednesday.
Shares of Williams-Sonoma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) rose sharply during Wednesday's session after the company reported <a href="https://www.benzinga.com/quote/WSM/earnings">better-than-expected third-quarter financial results.</a>
The company reported third-quarter adjusted earnings per share of $1.96, beating the analyst consensus of $1.78. Quarterly sales declined by 2.9% year-over-year to $1.8 billion, beating the street view of $1.79 billion. Comparable brand revenue was down 2.9% year-over-year.
Also, the company approved a $1 billion stock repurchase authorization.
Williams-Sonoma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) shares gained 22.7% to $168.48 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Red Cat Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NASDAQ">RCAT</a>) shares jumped 35.3% to $6.41. Palladyne AI and Red Cat expanded partnership for Teal Drones.</li>
<li>Kingsoft Cloud Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) shares surged 33.3% to $6.12. The company reported third-quarter earnings on Tuesday.</li>
<li>Alpha Teknova, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) rose 18.3% to $7.39.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) gained 18.2% to $4.0701.</li>
<li>Wix.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) gained 14.5% to $210.79 after the company reported better-than-expected third-quarter financial results and raised its FY24 revenue guidance. Also, multiple firms raised their respective price targets on the stock.</li>
<li>ATRenew Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RERE#NASDAQ">RERE</a>) gained 13.8% to $2.8000 following third-quarter results.</li>
<li>Global-E Online Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) shares rose 10.5% to $47.24 after the company reported better-than-expected quarterly financial results and raised its FY24 revenue outlook.</li>
<li>HUTCHMED (China) Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCM#NASDAQ">HCM</a>) gained 10.1% to $18.44. HUTCHMED announced the appointment of independent non-executive director and member of board committee.</li>
<li>Dolby Laboratories, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLB#NYSE">DLB</a>) gained 9.9% to $77.96 after the company reported better-than-expected fourth-quarter adjusted EPS results and issued FY25 EPS guidance above estimates.</li>
<li>Bruker Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) rose 9.2% to $52.69.</li>
<li>Azenta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZTA#NASDAQ">AZTA</a>) gained 9.2% to $44.68. Flex will replace Azenta in the S&amp;P MidCap 400, and Azenta will replace Envestnet in the S&amp;P SmallCap 600 effective prior to the opening of trading on Monday, Nov. 25.</li>
<li>Alignment Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) gained 6.6% to $11.82.</li>
<li>Flex Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLEX#NASDAQ">FLEX</a>) gained 6.3% to $39.69.</li>
<li>Keysight Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) rose 5.2% to $160.02 after the company reported better-than-expected quarterly financial results. Also, multiple firms raised their respective price targets on the stock.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42086593/wall-streets-most-accurate-analysts-spotlight-on-3-financial-stocks-with-over-9-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Financial Stocks With Over 9% Dividend Yields</a></li>
</ul>

Intraday Update

Markets

Movers

ALHC

AZTA

BRKR

FLEX

GLBE

KEYS

NOVA

RCAT

RERE

TKNO

Williams-Sonoma, Wix.com, Dolby Laboratories And Other Big Stocks Moving Higher On Wednesday

TD Cowen analyst John Kernan maintains Amer Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>) with a Buy and raises the price target from $21 to $23.

TD Cowen Maintains Buy on Amer Sports, Raises Price Target to $23

<a href="https://www.webull.com/">Webull</a>, a leading digital investment platform, today announced the expansion of its crypto futures offering with Coinbase Derivatives, LLC (Coinbase Derivatives), a futures exchange registered with the Commodity Futures Trading Commission (CFTC). Webull users in the U.S. will be able to trade futures contracts for Bitcoin (BTI), nano Bitcoin (BIT), Ethereum (ETI), and nano Ether (ET) directly on the Webull platform.
Webull launched futures and commodities trading in March 2024, which expands access and grants users the ability to further diversify their portfolios and manage risk more effectively. Webull will be bringing its advanced trading tools and Coinbase Derivatives' crypto futures offerings together for a seamless experience.

COIN

Webull Announces The Expansion Of Its Crypto Futures Offering With Coinbase Derivatives; Users In The U.S. Will Be Able To Trade Futures Contracts For Bitcoin (BTI), Nano Bitcoin (BIT), Ethereum (ETI), And Nano Ether (ET) Directly On The Webull Platform

Private equity billionaire Marc Rowan, who has emerged as a contender for the Treasury Secretary post, has openly admitted to being "out of my depth" when it comes to understanding cryptocurrency's role in the <a href="https://www.benzinga.com/trading-ideas/movers/24/11/42053981/trump-sec-pick-speculation-sends-this-altcoin-soaring-past-bitcoin-and-ethereum-in-daily-gains">U.S. financial system</a>.
What Happened: In a recent <a href="https://conversationswithtyler.com/episodes/marc-rowan/">podcast </a>with economist Tyler Cowen, the CEO of Apollo Global Management reflected on the complexities of cryptocurrency within the financial sector. 
Rowan criticized the limited understanding of crypto among prominent figures, including potential policymakers.
He said, "Out of my depth. Absolutely no idea," when asked directly about crypto's future role in the U.S. financial system.
Rowan further highlighted the potential for stablecoins and on-ramps to streamline the financial system but dismissed the relevance of alternative currencies in a regulated environment. 
"I see every opportunity for [stablecoins] to reduce the cost, to reduce the friction of dealing with the financial system," Rowan said.
However, he added, "In a KYC-AML world, I don't see a value for an alternative currency."
While Rowan was candid about his own lack of involvement in crypto through Apollo, his remarks raised questions about Warsh's readiness to tackle the growing importance of digital assets as a key component of financial policy.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42084945/coinbase-ceo-brian-armstrong-backs-doge-initiative-how-blockchain-could-transform-government-efficiency">Coinbase CEO Brian Armstrong Backs DOGE Initiative: How Blockchain Could Transform Government Efficiency</a>
Why It Matters: Prediction market Polymarket currently <a href="https://polymarket.com/event/who-will-trump-nominate-for-treasury-secretary">places</a> former Federal Reserve Governor Kevin Warsh as the leading candidate for the Treasury Secretary position, with a 50% chance.
Other contenders are hedge fund manager Scott Bessent (20%) and Rowan (20%). However, the volatile market reflects the participants&#8217; uncertainty, with Bessent&#8217;s and Rowan&#8217;s chances having traded above 50% in recent days.
Elon Musk also weighed in on the selection process, using his social media platform X to endorse Howard Lutnick, CEO of <a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks">Cantor Fitzgerald, for the position. </a>
While Lutnick was recently picked to lead the Commerce Department, Musk's public endorsement added another layer of speculation and reshaped the dynamics of the Treasury Secretary race.
Reports indicate that infighting among camps supporting Bessent and Lutnick has frustrated Trump, prompting him to consider alternatives. 
Rowan's candidacy has reportedly gained momentum following Lutnick's commerce appointment, while Bessent remains a strong competitor despite internal disputes.
The Treasury Secretary's role in shaping policies around these technologies will be critical as the U.S. faces growing competition from countries advancing their own <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40837533/put-in-the-cbdc-russian-central-bank-targets-july-2025-for-widespread-digital-ruble-use">central bank digital currencies (CBDCs)</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42072663/bitcoin-etf-options-could-smooth-volatility-become-available-on-robinhood-soon-expert-says">Bitcoin ETF Options Could Smooth Volatility, Become Available On Robinhood Soon, Expert Says</a></li>
</ul>
Image: Wikimedia

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Could Donald Trump's Potential Treasury Secretary Be 'Out Of His Depth' On Crypto Policy? Polymarket Traders Just Can't Decide On A Favorite

TD Cowen analyst Oliver Chen maintains Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Buy and raises the price target from $90 to $100.

TD Cowen Maintains Buy on Walmart, Raises Price Target to $100

Endeavour Silver shares are trading lower. The company entered into an agreement to sell 15,825,000 units of common stock to a syndicate of underwriters led by BMO Capital for gross proceeds of approximately $73 million.

TD Cowen analyst Jared Levine maintains Trinet Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNET#NYSE">TNET</a>) with a Buy and raises the price target from $92 to $104.

TNET

TD Cowen Maintains Buy on Trinet Group, Raises Price Target to $104

JFIN

Jiayin Group shares are trading lower after the company reported a year-over-year decrease in Q3 EPS results.

PDYN

Red Cat and Palladyne AI shares are trading higher after announcing a partnership expansion for teal drones.

XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) shares are trading slightly higher on Wednesday, following mixed third-quarter results from its rival, NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>).
NIO&#8217;s fiscal third quarter revenue totaled 18.67 billion yuan ($2.66 billion), down 2.1% year-over-year but up 7.0% from the previous quarter, missing the consensus estimate of $2.70 billion. The company posted an adjusted loss per share of 2.14 yuan (31 cents), a slight improvement from a <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/42084907/nio-q3-earnings-11-6-gain-in-vehicle-deliveries-margins-improve-issues-robust-q4-delivery-outlook" rel="noreferrer noopener">2.28 yuan loss in the same period last year.</a>
China&#8217;s $376 billion electric vehicle (EV) market continues to attract new entrants, including companies outside the traditional automotive sector, like makers of vacuum cleaners and hair dryers, according to a <a target="_blank" href="https://www.scmp.com/business/china-business/article/3286904/chinas-ev-market-lures-new-entrants-eyes-byds-crown-great-peril" rel="noreferrer noopener">report</a> from the South China Morning Post.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/emerging-markets/24/11/42068742/sony-eyes-japans-kadokawa-to-strengthen-gaming-and-anime-dominance" rel="noreferrer noopener">Sony Eyes Japan&#8217;s Kadokawa to Strengthen Gaming and Anime Dominance</a>
Despite optimism, the domestic EV market, the world&#8217;s largest, is projected to stagnate over the next two years in terms of revenue growth, the report read.
In contrast, XPeng is projecting robust fourth-quarter vehicle deliveries between 87,000 and 91,000, reflecting <a target="_blank" href="https://www.benzinga.com/24/11/42057872/xpeng-q3-earnings-over-18-topline-growth-deliveries-up-double-digit-percentage-margins-climb-over-15-ceo-eyes-ai-leadership" rel="noreferrer noopener">year-on-year growth of 44.6% to 51.3%</a>. The company also expects fourth-quarter revenue to range from 15.3 billion to 16.2 billion yuan, a year-on-year increase of 17.2% to 24.1%, surpassing the consensus estimate of 14.77 billion yuan.
XPeng&#8217;s flying car subsidiary, Xpeng Aeroht, made significant progress at the 15th China International Aviation and Aerospace Exhibition, securing 2,008 pre-orders for its <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/24/11/41946780/whats-going-on-with-xpeng-stock-wednesday" rel="noreferrer noopener">modular flying car, the Land Aircraft Carrier</a>.
Despite these developments, XPeng&#8217;s stock has dropped over 30% in the past year. Investors seeking exposure to XPeng can access the stock through the SPDR S&amp;P Kensho Smart Mobility ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAIL#NYSE">HAIL</a>).
Price Action: XPEV shares are trading higher by 2.04% to $12.78 at last check Wednesday.
Photo via Shutterstock
Also Read:
<ul>
<li><a href="https://www.benzinga.com//node/42082386" target="_blank" rel="noreferrer noopener">Tesla&#8217;s Chinese Rival Xpeng Vows To &#8216;Do Whatever It Takes To Be Competitive&#8217; Amid Donald Trump&#8217;s Tariff Threat</a></li>
</ul>

Equities

Media

HAIL

XPEV

What's Going On With XPeng Stock Today?

Whales with a lot of money to spend have taken a noticeably bearish stance on Microsoft.
Looking at options history for Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) we detected 10 trades.
If we consider the specifics of each trade, it is accurate to state that 30% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $468,781 and 5, calls, for a total amount of $513,015.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $200.0 to $480.0 for Microsoft during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Microsoft's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Microsoft's substantial trades, within a strike price spectrum from $200.0 to $480.0 over the preceding 30 days.
<h3>Microsoft 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732115900_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MSFT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$224.55</td>
<td>$222.65</td>
<td>$224.55</td>
<td>$200.00</td>
<td>$314.2K</td>
<td>173</td>
<td>4</td>
</tr>
<tr>
<td>MSFT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$82.95</td>
<td>$78.45</td>
<td>$81.17</td>
<td>$480.00</td>
<td>$121.7K</td>
<td>18</td>
<td>15</td>
</tr>
<tr>
<td>MSFT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$7.75</td>
<td>$7.75</td>
<td>$7.75</td>
<td>$410.00</td>
<td>$109.2K</td>
<td>7.5K</td>
<td>16</td>
</tr>
<tr>
<td>MSFT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/22/24</td>
<td>$4.95</td>
<td>$4.8</td>
<td>$4.93</td>
<td>$415.00</td>
<td>$98.7K</td>
<td>3.1K</td>
<td>1.0K</td>
</tr>
<tr>
<td>MSFT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$16.95</td>
<td>$16.75</td>
<td>$16.95</td>
<td>$365.00</td>
<td>$81.3K</td>
<td>999</td>
<td>0</td>
</tr>
</tbody>
</table>

<h3>About Microsoft</h3>
Microsoft develops and licenses consumer and enterprise software. It is known for its Windows operating systems and Office productivity suite. The company is organized into three equally sized broad segments: productivity and business processes (legacy Microsoft Office, cloud-based Office 365, Exchange, SharePoint, Skype, LinkedIn, Dynamics), intelligence cloud (infrastructure- and platform-as-a-service offerings Azure, Windows Server OS, SQL Server), and more personal computing (Windows Client, Xbox, Bing search, display advertising, and Surface laptops, tablets, and desktops).
Having examined the options trading patterns of Microsoft, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of Microsoft</h3>
<ul>
<li>Trading volume stands at 2,124,214, with MSFT's price down by -1.1%, positioned at $413.2.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 69 days.</li>
</ul>
<h3>Expert Opinions on Microsoft</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $508.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on Microsoft with a target price of $600. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Microsoft, which currently sits at a price target of $465. 
&#x2A; Maintaining their stance, an analyst from Bernstein continues to hold a Outperform rating for Microsoft, targeting a price of $500. 
&#x2A; An analyst from TD Cowen has decided to maintain their Buy rating on Microsoft, which currently sits at a price target of $475. 
&#x2A; An analyst from UBS has decided to maintain their Buy rating on Microsoft, which currently sits at a price target of $500. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Microsoft with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

MSFT

Decoding Microsoft's Options Activity: What's the Big Picture?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Chemomab Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmmb-stock-quote/">CMMB</a>) just reported results for the second quarter of 2024.<ul><li>Chemomab Therapeutics reported earnings per share of -26 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	The post <a href="https://investorplace.com/earning-results/2024/08/cmmb-stock-earnings-chemomab-therapeutics-for-q2-of-2024/">CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024

Chemomab Therapeutics (CMMB) has released an update. Chemomab Therapeutics reported promising results from its Phase 2 SPRING trial for CM-101, a p...

Chemomab's Positive Trial Results Boost Investor Confidence

Chemomab Therapeutics GAAP EPS of -$0.01 beats by $0.05

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Chemomab Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmmb-stock-quote/">CMMB</a>) just reported results for the second quarter of 2024.<ul><li>Chemomab Therapeutics reported earnings per share of -26 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	
	The post <a href="https://investorplace.com/earning-results/2024/08/cmmb-stock-earnings-chemomab-therapeutics-for-q2-of-2024/">CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Roth MKM analyst Jason Wittes maintained a Buy rating on Chemomab Therapeutics (CMMB – Research Report) today and set a price target of $9.00. The ...

Roth MKM Sticks to Their Buy Rating for Chemomab Therapeutics (CMMB)

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on CMMB stock, giving a Buy rating today. Michael Okunewitch has given h...

Chemomab Therapeutics: Promising Clinical Progress and Strategic Regulatory Pathways Support Buy Rating

Chemomab Therapeutics (CMMB) has released an update. Chemomab Therapeutics has announced that its shareholders approved a proposal to grant 126,848...

Chemomab Therapeutics Aligns Leadership Incentives with Shareholders

Chemomab Therapeutics (CMMB) announced that data from its Phase 2 SPRING trial in patients with primary sclerosing cholangitis was presented at the...

Chemomab highlights clincial activity of CM-101 at The Liver Meeting 2024

CMMB

Health Care

Press Releases

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Financing

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

Earnings

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Chemomab Therapeutics to Present at September 2024 Investor Conferences

Chemomab Therapeutics to Present at October 2024 Investor Conferences

Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024

Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update

Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Comments

Chemomab Therapeutics

Interés en corto

Chemomab Therapeutics (NASDAQ:CMMB) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL